

Hansa Medical

- PRESS RELEASE -
March 8, 2016

Farstorps Gård AB has divested Hansa Medical shares

Hansa Medical has been informed that a small group of long-term institutional investors have acquired shares from Farstorps Gård AB

Following the divestiture, Farstorps Gård AB holds approximately 1 million shares in Hansa Medical, equivalent to approximately 3 percent of the number of outstanding shares in Hansa Medical. Farstorps Gård AB has informed Hansa Medical that Farstorps Gård AB will remain a long-term shareholder in the company and that Farstorps Gård has committed not to divest any further shares within the next 12 months (a so called 12 month lock-up period).

The information in this press release is disclosed pursuant to the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was released for public disclosure on March 8, 2016 at 08.30 CET.

About Hansa Medical AB

Hansa Medical is a biopharmaceutical company focusing on novel immunomodulatory enzymes. The lead project IdeS is an antibody-degrading enzyme in clinical development, with potential use in transplantation and rare autoimmune diseases. Additional projects focus on development of new antibody modulating enzymes, as well as HBP, a diagnostic biomarker for prediction of severe sepsis at emergency departments that is already introduced on the market. The company is based in Lund, Sweden. Hansa Medical's share (ticker: HMED) is listed on Nasdaq Stockholm.

For further information, please contact:

Hansa Medical AB
Göran Arvidson, CEO
Mobile: +46 70-633 30 42
E-mail: goran.arvidson@hansamedical.com

www.hansamedical.com